Fianlimab
R3767-ONC-2266
Phase 2 small_molecule active
Quick answer
Fianlimab for Resectable Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active